IndraLab

Statements


| 1 2

sparser
"A virtual screen shows that the small molecule Imatinib could potentially interact with catalytic MPN domain of MYSM1 to inhibit BCa cell growth via MYSM1-ERα axis."

sparser
"Virtual screening identified Imatinib as a small molecule capable of interacting with the catalytic MPN domain of MYSM1, and this effectively inhibited breast cancer cell growth, highlighting the MYSM1-ERα axis as a promising target to overcome endocrine independence in breast cancer [ xref ]."
| PMC

reach
"MYSM1 physically associates with ERalpha in breast cancer cells."